Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.67 |
| ▸ | CLEC4M | Q9H2X3 | 1/20 | 0.52 |
| ▸ | GABRA1 | P14867 | 3/20 | 0.50 |
| ▸ | GABRB2 | P47870 | 3/20 | 0.50 |
| ▸ | GABRB1 | P18505 | 2/20 | 0.49 |
| ▸ | GABRA3 | P34903 | 2/20 | 0.49 |
| ▸ | JAK2 | O60674 | 1/20 | 0.45 |
| ▸ | JAK3 | P52333 | 1/20 | 0.45 |
| ▸ | MEN1 | O00255 | 2/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | TP53 | P04637 | 1/20 | 0.43 |
| ▸ | HPGD | P15428 | 1/20 | 0.43 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.43 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.43 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.43 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.43 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.43 |
| ▸ | CTNNB1 | P35222 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16229083 | 0.87 | KDM4E (0.51) | KDM4ECLEC4MGABRA1GABRB2GABRB1 | |
| SCHEMBL2285923 | 0.84 | CLEC4M (0.55) | KDM4ECLEC4MGABRA1GABRB2GABRB1 | |
| SCHEMBL2970181 | 0.83 | CLEC4M (0.58) | KDM4ECLEC4MGABRA1GABRB2GABRB1 | |
| SCHEMBL396948 | 0.82 | CLEC4M (0.56) | KDM4ECLEC4MGABRA1GABRB2GABRB1 | |
| SCHEMBL12606661 | 0.82 | PBRM1 (0.46) | KDM4EMEN1KMT2AALDH1A1TP53 | |
| SCHEMBL28752415 | 0.81 | NR4A2 (0.59) | KDM4ECLEC4MGABRA1GABRB2GABRB1 | |
| SCHEMBL4742144 | 0.81 | KDM4E (1.00) | KDM4ECLEC4MGABRA1GABRB2GABRB1 | |
| SCHEMBL1353154 | 0.80 | CYP1A2 (0.51) | KDM4EMEN1KMT2AALDH1A1HPGD | |
| SCHEMBL396665 | 0.80 | CLEC4M (0.57) | KDM4ECLEC4MGABRA1GABRB2GABRB1 | |
| SCHEMBL29464955 | 0.79 | ALDH1A1 (0.46) | KDM4EMEN1KMT2AALDH1A1HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 129 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160022665-A2 | Pharmaceutical Compositions and Administrations Thereof | VERTEX PHARMACEUTICALS INCORPORATED | 2016-01-28 | — | — | US | disclosed |
| US-20160022665-A2 | Pharmaceutical Compositions and Administrations Thereof | VERTEX PHARMACEUTICALS INCORPORATED | 2016-01-28 | — | — | US | disclosed |
| US-20160022665-A2 | Pharmaceutical Compositions and Administrations Thereof | VERTEX PHARMACEUTICALS INCORPORATED | 2016-01-28 | — | — | US | disclosed |
| US-20160022664-A2 | Pharmaceutical Compositions and Administrations Thereof | VERTEX PHARMACEUTICALS INCORPORATED | 2016-01-28 | — | — | US | disclosed |
| US-20160022664-A2 | Pharmaceutical Compositions and Administrations Thereof | VERTEX PHARMACEUTICALS INCORPORATED | 2016-01-28 | — | — | US | disclosed |
| US-20160022664-A2 | Pharmaceutical Compositions and Administrations Thereof | VERTEX PHARMACEUTICALS INCORPORATED | 2016-01-28 | — | — | US | disclosed |
| US-20150164883-A1 | PHARMACEUTICAL COMPOSITIONS AND ADMINISTRATIONS THEREOF | VERTEX PHARMA (US) | 2015-06-18 | — | — | US | disclosed |
| US-20150164881-A1 | Pharmaceutical Compositions and Administrations Thereof | VERTEX PHARMA (US) | 2015-06-18 | — | — | US | disclosed |
| US-20150164883-A1 | PHARMACEUTICAL COMPOSITIONS AND ADMINISTRATIONS THEREOF | VERTEX PHARMA (US) | 2015-06-18 | — | — | US | disclosed |
| US-20150164883-A1 | PHARMACEUTICAL COMPOSITIONS AND ADMINISTRATIONS THEREOF | VERTEX PHARMA (US) | 2015-06-18 | — | — | US | disclosed |
| US-20100130547-A1 | SOLID FORMS OF N-(4-(7-AZABICYCLO[2.2.1]HEPTAN-7-YL)-2-(TRIFLUORORMETHYL)PHENYL)-4-OXO-5-(TRIFLUOROMETHYL)-1,4-DIHYROQUINOLINE-3-CARBOXAMIDE | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2010-05-27 | — | — | US | disclosed |
| US-20100113508-A1 | Modulators of Cystic Fibrosis Transmembrane Conductance Regulator | VERTEX PHARMACEUTICALS, INCORPORATED (US) | 2010-05-06 | — | — | US | disclosed |
| US-20100113508-A1 | Modulators of Cystic Fibrosis Transmembrane Conductance Regulator | VERTEX PHARMACEUTICALS, INCORPORATED (US) | 2010-05-06 | — | — | US | disclosed |
| US-20100113508-A1 | Modulators of Cystic Fibrosis Transmembrane Conductance Regulator | VERTEX PHARMACEUTICALS, INCORPORATED (US) | 2010-05-06 | — | — | US | disclosed |
| US-20100113509-A1 | MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2010-05-06 | — | — | US | disclosed |
| US-20100113509-A1 | MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2010-05-06 | — | — | US | disclosed |
| US-20100113509-A1 | MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2010-05-06 | — | — | US | disclosed |
| WO-2010048564-A1 | MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2010-04-29 | — | — | WO | disclosed |
| WO-2010048573-A1 | SOLID FORMS OF N-(4-(7-AZABICYCLO[2.2.1]HEPTAN-7-YL)-2-(TRIFLUOROMETHYL)PHENYL)-4-OXO-5-(TRIFLUOROMETHYL)-1,4-DIHYDROQUINOLINE-3-CARBOXAMIDE | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2010-04-29 | — | — | WO | disclosed |
| WO-2010048526-A2 | MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR | VERTEX PHARMACEUTICALS, INCORPORATED (US) | 2010-04-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150164883-A1 | PHARMACEUTICAL COMPOSITIONS AND ADMINISTRATIONS THEREOF | CFTR, ABCB11, SLC26A4 | KDM4E 4080/4885CLEC4M 2205/4885GABRA1 2272/4885 |
| US-20100113508-A1 | Modulators of Cystic Fibrosis Transmembrane Conductance Regulator | CFTR, SCNN1G, SCNN1B | KDM4E 4213/4885CLEC4M 1219/4885GABRA1 760/4885 |
| US-20160022665-A2 | Pharmaceutical Compositions and Administrations Thereof | CFTR, ABCB11, SLC26A4 | KDM4E 4080/4885CLEC4M 2205/4885GABRA1 2272/4885 |
| US-20160022664-A2 | Pharmaceutical Compositions and Administrations Thereof | CFTR, ABCB11, ABCC5 | KDM4E 4614/4885CLEC4M 2715/4885GABRA1 1861/4885 |
| US-20150164881-A1 | Pharmaceutical Compositions and Administrations Thereof | CFTR, ABCB11, ABCC5 | KDM4E 4614/4885CLEC4M 2715/4885GABRA1 1861/4885 |
| US-20100113509-A1 | MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR | CFTR, SCNN1G, SCNN1B | KDM4E 4213/4885CLEC4M 1219/4885GABRA1 760/4885 |
| US-20100130547-A1 | SOLID FORMS OF N-(4-(7-AZABICYCLO[2.2.1]HEPTAN-7-YL)-2-(TRIFLUORORMETHYL)PHENYL)-4-OXO-5-(TRIFLUOROMETHYL)-1,4-DIHYROQUINOLINE-3-CARBOXAMIDE | H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, CYP4B1, AZI2 | KDM4E 288/4885CLEC4M 2993/4885GABRA1 1376/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.